Best practice templates for E and L protocols, reports and regulatory responses Best practice templates for E and L protocols, reports and regulatory responses In the pharmaceutical and biopharmaceutical industries, ensuring the safety and efficacy of drug products packaged in various materials is paramount. Extractables and leachables (E and L) assessments are critical components in safeguarding product integrity while meeting regulatory requirements set forth by global health authorities such as the FDA, EMA, and MHRA. This article provides a comprehensive overview of best practices for E and L protocols, reports, and regulatory responses, aligning with FDA E and L expectations…

Developing E and L Justifications for Lifecycle Changes in Packaging Materials Developing E and L Justifications for Lifecycle Changes in Packaging Materials Introduction to Extractables and Leachables (E and L) in Pharmaceutical Packaging The pharmaceutical industry is under constant pressure to ensure the safety, efficacy, and quality of drug products. An integral aspect of this quality assurance pertains to the use of packaging materials that can interact with the drug substances they contain. Extractables and leachables (E and L) present a crucial area of concern, as they can pose significant risks to drug product integrity and patient safety. The FDA,…

Handling Unexpected Leachable Findings During Stability or Post Market Testing Handling Unexpected Leachable Findings During Stability or Post Market Testing In the pharmaceutical industry, the integrity and safety of drug products are paramount. This is particularly true when addressing extractables and leachables (E&L) packaging, which can impact the safety and efficacy of pharmaceutical products. This article aims to elucidate the processes and considerations necessary for handling unexpected leachable findings during stability or post-market testing. It focuses on compliance with regulatory agencies such as the FDA, the EMA, and the MHRA while providing insights into best practices for E&L safety assessments….

Tamper Evidence Technologies: Labels, Shrink Bands, Seals, and Cartons Tamper Evidence Technologies: Labels, Shrink Bands, Seals, and Cartons The pharmaceutical industry operates under stringent regulations to ensure product safety, efficacy, and integrity. A critical aspect of this regulatory landscape is the implementation of tamper evidence technologies in packaging systems. This article serves as a comprehensive guide for pharmaceutical professionals, encompassing regulatory requirements laid out by the FDA, EMA, and MHRA, while detailing best practices in packaging system qualification and Container Closure Integrity (CCI) validation. Understanding Tamper Evidence Technologies Tamper evidence technologies are designed to deter unauthorized access to pharmaceutical products…

Aggregation Strategies Cases, Pallets and Shipping Containers under DSCSA Aggregation Strategies Cases, Pallets and Shipping Containers under DSCSA The Drug Supply Chain Security Act (DSCSA) enacted in 2013, aims to enhance FDA traceability requirements and bolster anti-counterfeiting measures within the pharmaceutical supply chain. One of the pivotal components of the DSCSA is serialization, which mandates that manufacturers assign a unique identifier to each prescription drug package. As the pharmaceutical industry continues to evolve, implementing robust aggregation strategies has become critical to ensuring compliance with DSCSA and harmonizing with global standards, including the EU Falsified Medicines Directive (FMD). This article will…

Integrating Serialization Systems with MES, ERP and Warehouse Operations Integrating Serialization Systems with MES, ERP and Warehouse Operations The integration of serialization systems with Manufacturing Execution Systems (MES), Enterprise Resource Planning (ERP) software, and warehouse operations is crucial in ensuring compliance with FDA traceability requirements and maintaining efficient supply chain management in the pharmaceutical industry. This article provides an in-depth exploration of serialization in relation to the Drug Supply Chain Security Act (DSCSA), emphasizing best practices for tamper-evident packaging, data integrity, and anti-counterfeiting controls across the US, EU, and UK regulatory frameworks. Understanding Pharma Serialization and Regulatory Compliance The implementation…

Case studies of serialization and traceability gaps highlighted by regulators Case studies of serialization and traceability gaps highlighted by regulators The pharmaceutical industry is increasingly navigating complex regulatory landscapes centered around serialization and traceability. Recent case studies have highlighted significant gaps in these areas, prompting regulatory bodies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to increase scrutiny of pharmaceutical companies’ practices. This article aims to elucidate the key issues surrounding serialization, traceability, and tamper-evident packaging, while aligning with both FDA and EMA…

DSCSA Requirements for Manufacturers, Repackagers, Wholesalers and Dispensers Understanding DSCSA Requirements for Pharma Companies The Drug Supply Chain Security Act (DSCSA) establishes a framework for the United States’ drug supply chain to enhance the detection and prevention of counterfeit drugs. As regulatory requirements evolve globally, pharmaceutical manufacturers, repackagers, wholesalers, and dispensers must comply with the DSCSA and ensure adherence to stringent traceability and anti-counterfeiting controls. This article elaborates on DSCSA requirements and how they align with international regulations, including the European Union’s Falsified Medicines Directive (EU FMD), particularly focusing on the implementation of serialization, tamper-evident packaging, and data integrity. Overview…

How to implement unit level serialization on blister, bottle and vial lines How to Implement Unit Level Serialization on Blister, Bottle and Vial Lines In the global pharmaceutical landscape, effective serialization is crucial for compliance with regulatory requirements and to combat counterfeiting. Serializing units of medication enhances supply chain traceability, thus ensuring compliance with laws such as the Drug Supply Chain Security Act (DSCSA) in the United States and the EU Falsified Medicines Directive (FMD) in Europe. This article provides a thorough guide on implementing unit-level serialization on blister, bottle, and vial lines, while considering FDA traceability requirements and international…

Packaging Line Readiness Assessments Before Go Live with Serialization Systems Packaging Line Readiness Assessments Before Go Live with Serialization Systems In an era marked by increasing regulatory scrutiny and technological advancements, the need for effective serialization systems in pharmaceutical packaging is more pertinent than ever. The Drug Supply Chain Security Act (DSCSA) in the United States mandates stringent compliance measures to ensure the traceability of pharmaceutical products. This regulatory framework aims to combat counterfeit drugs, enhance supply chain security, and protect public health. This article serves as a comprehensive guide for pharmaceutical professionals involved in the preparation and assessment of…